An interventional study of Analysis of inhibitory control in Bipolar Disorder and Major Depressive Disorder, sponsored by CHU de Reims. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by CHU de Reims · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.
Among the 104 studies in Bipolar Disorder with a site in France, this one is the 46th largest by planned enrollment of the 79 interventional ones that give a count, is one of 7 that started in 2026, is one of 56 with no phase, reaches primary completion later than 33 of the 37 other live ones, and was the 100th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier St Anne · Sites in France
Ages 18+
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Hospital Center Guillaume Régnier · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18–45 · Healthy volunteers
Centre hospitalier de Ville-Evrard, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 16 · Phase 4 2
First in 2004; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 170 across the 79 interventional studies, 100 across the 25 observational. Of the 46 that completed or were terminated, 12 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 104 have an industry lead sponsor. The 10 most frequent:
CHU de Reims is the lead sponsor of 276 studies on the registry; 50 are open to participants now.
CHU de Reims has 6 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
10 of the studies in Bipolar Disorder with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT04917419Centre Hospitalier Henri LaboritNursing Care of Bipolar Patients With Sleeping Disorders Using Luminotherapy and /or Psychoeducation Program (BIPLUMINO) | 2026-12 |
| NCT05878730Assistance Publique - Hôpitaux de ParisMelatonin and Response to Lithium | 2026-12 |
| NCT06059313Nantes University HospitalPremorbid Personality Profile of Patients With Cognitive and Behavioral Disorders | 2026-12-14 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies in Bipolar Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Bipolar disorder and unipolar depressive disorder are two chronic mood disorders associated with a significant social impact, even during euthymic phases. Their differential diagnosis remains complex, particularly when bipolar disorder begins with a depressive episode. Identifying distinctive markers between these pathologies therefore represents a major clinical and economic challenge, as appropriate mood-stabilizing treatment can reduce healthcare costs and improve patients' functional outcomes.
Among potential biomarkers, executive functions-and more specifically inhibition-have received particular attention. Inhibitory deficits are observed in both disorders, including during euthymic states, and also among first-degree relatives, suggesting their potential as cognitive and cerebral endophenotypes. These deficits may help explain the difficulties in emotion regulation and impulsivity frequently observed in mood disorders.
Two components of inhibition are distinguished:
The study is expected to reveal:
These findings should provide a better understanding of the differential neurocognitive bases of mood disorders. Identifying specific cognitive and neural profiles could contribute to more accurate differential diagnosis and to the personalization of therapeutic interventions, particularly through cognitive remediation strategies targeting executive and emotional deficits.
Bipolar disorder (BD) and unipolar depressive disorder (UDD) are chronic mood disorders that cause significant functional and social impairment, even during euthymic phases. The differential diagnosis between these two conditions remains challenging, especially when bipolar disorder initially manifests with a depressive episode, the most frequent onset pattern. Identifying reliable biomarkers that distinguish BD from UDD is therefore a major clinical and scientific objective. Early and appropriate introduction of mood-stabilizing treatments is associated with improved long-term outcomes and reduced healthcare costs through fewer hospitalizations.
Scientific Background and Rationale:
Executive dysfunctions, particularly inhibitory control deficits, have been consistently observed in both BD and UDD, including during remission. Similar deficits in first-degree relatives suggest that these alterations could represent cognitive or neural endophenotypes. Inhibition, defined as the ability to suppress a dominant or prepotent response, plays a central role in emotion regulation.
Inhibitory control can be divided into two complementary components:
Neuroimaging studies in healthy populations have revealed distinct but overlapping neural networks underlying these two processes. However, data on BD and UDD remain limited and sometimes inconsistent, particularly regarding the differential involvement of these two components and their modulation by emotional context.
Objectives:
The primary objective of this study is to investigate, using functional magnetic resonance imaging (fMRI), the brain circuits underlying the two mechanisms of inhibitory control - behavioral inhibition and interference control - in both their cognitive and emotional components, among euthymic patients with BD or UDD, compared with matched healthy controls.
Secondary objectives include:
Study Design:
This is a monocentric, prospective, cross-sectional study including four participant groups: patients with BD, patients with UDD, and their respective matched control groups. Each participant will complete three study visits:
Experimental Paradigms and Imaging Procedures:
Two validated cognitive paradigms will be used:
MRI data will be acquired using a 3-Tesla scanner. Functional sequences will use gradient-echo echo-planar imaging optimized for BOLD contrast, with a temporal resolution of approximately 2 seconds and a spatial resolution of \~3 mm isotropic. High-resolution T1-weighted anatomical images (1 mm isotropic) will be acquired for normalization and morphometric analysis.
Data Analysis:
Preprocessing and statistical analyses will be performed using standard neuroimaging software. Data will undergo motion correction, spatial normalization to MNI space, and Gaussian smoothing.
First-level analyses will be conducted using a general linear model to model activation for cognitive and emotional conditions.
Second-level (group) analyses will use hierarchical mixed-effects models to identify between-group differences in neural activation patterns (BD vs. UDD vs. controls). Correlation analyses will explore relationships between brain activation, cognitive performance, and clinical variables.
Statistical significance will be set at p \< 0.05 family-wise error corrected for multiple comparisons, and p \< 0.001 uncorrected for exploratory analyses.
Innovation and Expected Outcomes:
This study is among the first to jointly investigate behavioral and interference components of inhibitory control in both cognitive and emotional domains in euthymic BD and UDD patients. The combination of neuropsychological and fMRI approaches will:
Group 1 and 2: Bipolar patients, Depressive patients
Inclusion criteria:
Exclusion criteria:
Group 3 and 4: Healthy control participants
Inclusion criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with a diagnosis of bipolar disorder
Behavioral: Analysis of inhibitory control
Patients with a diagnosis of major depressive disorder
Behavioral: Analysis of inhibitory control
Healthy control participants matched to group 1
Behavioral: Analysis of inhibitory control
Healthy control participants matched to group 2
Behavioral: Analysis of inhibitory control
Investigation of neurofunctional characterization of inhibitory control using a comprehensive clinical, cognitive assessment and task-based MRI exams
fMRI activations during an behavioral inhibition task (emotional stop signal task)
Participants will perform a gender discrimination task on emotional and non-emotional faces. Under Go conditions, the participant must respond. Under non-Go conditions, the frame of the image changes color and the participant must not respond. The faces express neutrality (50%) or anger (50%).
Time frame: Day 0
fMRI activations during an emotional interference control (emotional Flanker task)
Participants were instructed to discriminate the gender of a target stimulus during an emotional Flanker task. The stimuli consist of faces expressing a neutral or angry emotion. The central face (the target) may display the same emotion (congruent condition) or a different emotion (incongruent condition) from the faces on the right and left (two flankers). Participants must say, as quickly and accurately as possible, what the gender of the central face is
Time frame: Day 0
Psychological profiles: depression
Evaluated through the Hamilton Depression Rating Scale (HAM-D). HAM-D is a widely used self-report scale to assess depressive symptoms consisting of 21 items, which has been validated in French. The total score is obtained by adding the scores of the 17 first items, the score ranging from 0 to 52, with higher scores indicating greater depression symptoms.
Time frame: Day 0
Psychological profiles: mania
Evaluated through the Young Mania Rating Scale (YMRS). The YMRS is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items, the score ranging from 0 to 60 and higher scores indicating greater manic symptoms.
Time frame: Day 0
Psychological profiles: anxiety symptoms
Anxiety severity is assessed with the Spielberger State-Trait Inventory (STAI) which is a 40-item scale, using a 4-point Likert scale for each item. This scale was used to measure both trait anxiety (how dispositionally anxious a person is across time and situations) and state anxiety (how anxious a person is feeling at a particular moment). The total score is obtained by adding items, the score ranging from 20 to 80. Higher scores indicate greater anxiety symptoms.
Time frame: Day 0
Social functioning: quality of life
Evaluated through the World Health Organization Quality of Life (WHOQOL-BREF) quality of life assessment. The WHOQOL-BREF consists of 26 items scored in four domains: physical, psychological, social relationships, and environment. The score ranges from 0 to 100 with the higher score indicating a better quality of life.
Time frame: Day 0
Executive functions: verbal inhibition performance
Evaluated through the Hayling Sentence Completion Test. The HCST consists of two sets of 15 sentences each having the last word missing. In the first section the examiner reads each sentence aloud and the participant has to simply complete the sentences, yielding a simple measure of response initiation speed. The second part of the Hayling requires participants to complete a sentence with a nonsense ending word (and suppress a sensible one), giving measures of response suppression ability and thinking time. The number of correct answers and the total time are recorded for each part. The higher the number of correct answers, the better the performance. The longer the response time, the lower the performance. For each part, the score ranges from 0 to 15.
Time frame: Day 0
Started Nov 2026 (actual). Primary completion is estimated for Nov 2029, 36 months after the start.
Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 36 months is close to that.
Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jun 2026 → Nov 2026, primary completion Sep 2029 → Nov 2029 and completion Dec 2029 → Jan 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.